CA2868930C - Pyrimidine derivatives for the treatment of bacterial diseases - Google Patents
Pyrimidine derivatives for the treatment of bacterial diseases Download PDFInfo
- Publication number
- CA2868930C CA2868930C CA2868930A CA2868930A CA2868930C CA 2868930 C CA2868930 C CA 2868930C CA 2868930 A CA2868930 A CA 2868930A CA 2868930 A CA2868930 A CA 2868930A CA 2868930 C CA2868930 C CA 2868930C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- optionally substituted
- halo
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166140 | 2012-04-30 | ||
| EP12166140.9 | 2012-04-30 | ||
| PCT/EP2013/058980 WO2013164337A1 (en) | 2012-04-30 | 2013-04-30 | New compounds and new use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2868930A1 CA2868930A1 (en) | 2013-11-07 |
| CA2868930C true CA2868930C (en) | 2023-11-28 |
Family
ID=48430690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2868930A Active CA2868930C (en) | 2012-04-30 | 2013-04-30 | Pyrimidine derivatives for the treatment of bacterial diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9725432B2 (enExample) |
| EP (1) | EP2938599B1 (enExample) |
| JP (2) | JP6349303B2 (enExample) |
| KR (1) | KR102186851B1 (enExample) |
| CN (1) | CN104487425B (enExample) |
| AR (1) | AR090880A1 (enExample) |
| AU (1) | AU2013255843B2 (enExample) |
| BR (1) | BR112014026776B1 (enExample) |
| CA (1) | CA2868930C (enExample) |
| EA (1) | EA030899B1 (enExample) |
| ES (1) | ES2676189T3 (enExample) |
| IN (1) | IN2014MN02363A (enExample) |
| MX (1) | MX358189B (enExample) |
| NZ (2) | NZ724424A (enExample) |
| TW (1) | TWI598099B (enExample) |
| WO (1) | WO2013164337A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598099B (zh) * | 2012-04-30 | 2017-09-11 | 健生科學愛爾蘭無限公司 | 新化合物及其新用途 |
| WO2019121352A1 (en) * | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| ATE366045T1 (de) | 2002-03-15 | 2007-07-15 | Ciba Sc Holding Ag | Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen |
| DE102004003493A1 (de) | 2004-01-23 | 2005-08-11 | Bayer Cropscience Ag | 5-Phenylpyrimidine |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| BRPI0912029A2 (pt) * | 2008-02-01 | 2020-06-30 | Orchid Research Laboratories Limited | novos heterociclos |
| WO2011061214A1 (en) * | 2009-11-18 | 2011-05-26 | Fab Pharma Sas | Novel heterocyclic acrylamides and their use as pharmaceuticals |
| WO2011060976A1 (en) * | 2009-11-20 | 2011-05-26 | Universite De Liege | Tryptamine-derived compounds as antibacterial agents |
| TWI487709B (zh) * | 2009-12-18 | 2015-06-11 | Basilea Pharmaceutica Ag | 三環抗生素 |
| TWI598099B (zh) * | 2012-04-30 | 2017-09-11 | 健生科學愛爾蘭無限公司 | 新化合物及其新用途 |
-
2013
- 2013-04-29 TW TW102115187A patent/TWI598099B/zh not_active IP Right Cessation
- 2013-04-29 AR ARP130101454A patent/AR090880A1/es active IP Right Grant
- 2013-04-30 CA CA2868930A patent/CA2868930C/en active Active
- 2013-04-30 MX MX2014013165A patent/MX358189B/es active IP Right Grant
- 2013-04-30 JP JP2015509418A patent/JP6349303B2/ja active Active
- 2013-04-30 WO PCT/EP2013/058980 patent/WO2013164337A1/en not_active Ceased
- 2013-04-30 US US14/397,501 patent/US9725432B2/en active Active
- 2013-04-30 AU AU2013255843A patent/AU2013255843B2/en not_active Ceased
- 2013-04-30 BR BR112014026776-6A patent/BR112014026776B1/pt not_active IP Right Cessation
- 2013-04-30 CN CN201380022591.6A patent/CN104487425B/zh active Active
- 2013-04-30 EP EP13722329.3A patent/EP2938599B1/en active Active
- 2013-04-30 IN IN2363MUN2014 patent/IN2014MN02363A/en unknown
- 2013-04-30 NZ NZ724424A patent/NZ724424A/en not_active IP Right Cessation
- 2013-04-30 KR KR1020147029515A patent/KR102186851B1/ko not_active Expired - Fee Related
- 2013-04-30 ES ES13722329.3T patent/ES2676189T3/es active Active
- 2013-04-30 NZ NZ700507A patent/NZ700507A/en not_active IP Right Cessation
- 2013-04-30 EA EA201491992A patent/EA030899B1/ru not_active IP Right Cessation
-
2017
- 2017-08-04 US US15/668,773 patent/US10221157B2/en active Active
-
2018
- 2018-03-20 JP JP2018052573A patent/JP6622839B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3019482B1 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| JP2018519302A (ja) | 抗菌化合物 | |
| UA130447C2 (uk) | Антагоністи рецептора меланокортину 2 підтипу (mc2r) і шляхи їх застосування | |
| CA2693926A1 (en) | Dna-pk inhibitors | |
| MX2013001582A (es) | Compuesto heterociclico. | |
| JP2009513691A (ja) | リポキシゲナーゼ阻害剤としてのトリアゾール化合物 | |
| EP2882739B1 (en) | New antibacterial compounds | |
| CA2868930C (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| US20080090836A1 (en) | Pyrazole Compounds Useful In The Treatment Of Inflammation | |
| CN121532192A (zh) | 犬Janus激酶抑制剂及其用途 | |
| HK1208454B (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| KR20150099772A (ko) | 항균성 화합물 | |
| CN120025283A (zh) | 酰胺类化合物及其用途 | |
| US20080227787A1 (en) | Use of New Lipoxygenase Inhibitors | |
| HK1224919A1 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| HK1224919B (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180116 |
|
| EEER | Examination request |
Effective date: 20180116 |
|
| EEER | Examination request |
Effective date: 20180116 |
|
| EEER | Examination request |
Effective date: 20180116 |
|
| EEER | Examination request |
Effective date: 20180116 |
|
| EEER | Examination request |
Effective date: 20180116 |
|
| EEER | Examination request |
Effective date: 20180116 |
|
| EEER | Examination request |
Effective date: 20180116 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 |